1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
"Development of Senotherapeutic Agents for Cancer Treatment (NCI 446)" is currently closed and not accepting applications.
Development of Senotherapeutic Agents for Cancer Treatment (NCI 446) is sponsored by National Cancer Institute (NCI) Small Business Innovation Research (SBIR) Program. This opportunity supports mission-aligned projects and measurable outcomes.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
The SBIR and STTR programs were reauthorized on April 13, 2026. Currently, NIH has no active SBIR or STTR Notices of Funding Opportunity (NOFOs). Future NOFOs are forecasted at Grants.
gov prior to opening for applications. The next standard receipt date is September 5, 2026. Going Beyond Funding for Next-Generation Cancer Technologies Boosting the Economy and Driving Innovation Between 1998 and 2018, NCI SBIR/STTR awardees fueled $26.
1 billion in economic output, 100,000+ jobs, and breakthrough cancer technologies. Latest Opportunities with SBIR NCI STEP Deadline Approaching Apply for SBIR/STTR application support and entrepreneurship training through NCI STEP by at Friday, May 15, 2026. Upcoming ASGCT Poster Presentation Connect with the NCI SBIR team during the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting.
Biomedical researchers at Illumina are developing next-generation tools to analyze genetic variation and function on a massive scale. Illumina used NCI SBIR funding to develop their next generation sequencing technology.
According to the current listing, eligibility includes: Small businesses with hit or lead compounds in hand. Confirm the full requirements in the official notice before applying.
The current listing shows not specified (SBIR Phase I/II typically up to $250,000/$1,750,000, but varies). Verify award ceilings, matching requirements, and allowable costs in the official notice.
The published deadline was September 5, 2026, which has passed. Check the official notice for any future application windows before investing time in a proposal.
Development of Senotherapeutic Agents for Cancer Treatment (NCI 446) is funded by National Cancer Institute (NCI) Small Business Innovation Research (SBIR) Program. Verify program details on the funder's official page before applying.
Yes — this listing is flagged as national in scope, so applicants across the U.S. may apply, subject to the sponsor's other eligibility criteria.
Applications go through the funder's official portal — the Apply Now link on this page goes there directly.
Past winners and funding trends for this program
The Small Business Innovation and Economic Security Act of 2026 saved the programs after a six-month lapse, but it also added $30M strategic-breakthrough awards, per-company proposal caps, and mandatory national-security screening. Here is what changed across all eleven SBIR agencies — and what it means for your next proposal.
Read articleS.3971 reauthorizes SBIR/STTR through 2031 with strategic breakthrough funding, security screening, and proposal caps. What changed and how to compete.
Read articleThe SBIR/STTR reauthorization through 2031 introduces Strategic Breakthrough Awards up to $30M, proposal caps, and enhanced security vetting. What small businesses need to know now.
Read article